Detail akcie Crinetics Pharma Rg online

Business Summary: Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Crinetics Pharmaceuticals Inc revenues increased 48% to $1.5M. Net loss increased 57% to $342.5M. Revenues reflect PHARMACEUTICAL PREPARATIONS segment increase from $0K to $1.5M. Higher net loss reflects PHARMACEUTICAL PREPARATIONS segment loss increase from $87.8M to $383.1M. Basic Earnings per Share excluding Extraordinary Items decreased from -$2.82 to -$3.65.